The full text of this article

 

FDA drug approval intervals from 1997 to 2006: analysis and comparison during information technology implementation
by John F. Kros, Christopher M. Keller
International Journal of Electronic Healthcare (IJEH), Vol. 5, No. 2, 2009

 

Abstract: The implementation of new Information Technology (IT) has been a persistent target for improving FDA review intervals. Three main categories of new drugs are studied: New Drug Application (NDA), the Supplemental New Drug Application (SNDA) and the Abbreviated New Drug Application (ANDA). This paper finds that the median review time for an ANDA was significantly longer than that of an NDA and SDNA. A comparison of application class medians revealed significant differences. Regardless of the recent focus on IT implementations at the FDA pertaining to review intervals, that focus has not yet yielded a statistically significant improvement in review times.

Online publication date: Tue, 10-Nov-2009

 

is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

 
Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

 
Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Electronic Healthcare (IJEH):
Login with your Inderscience username and password:

 

    Username:        Password:         

Forgotten your password?


 
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

 
If you still need assistance, please email subs@inderscience.com